At TRACER we are specialized in first-in-human studies with the use of nuclear and optical molecular imaging techniques. By labeling an antibody, small molecule, peptide, nanoparticle, protein, or any other compound of interest with a fluorescent dye or a radionuclide, fast in human data can be obtained with an indication of the potential efficacy of the novel drug, even before the classical phase 1-3 clinical trials. This can lead to a more efficient and less costly drug development process. We assist our sponsors in the labeling of their lead compounds and execute first-in-human studies to visualize and quantify the biodistribution and pharmacokinetics of the compound. With this information a “ go/no-go” decision can be made before the compound proceeds to the next phase in clinical development where costs are larger and time is valuable. Early in-human studies are approved by the EMA and FDA through the so-called principle of microdosing. It allows you to often skip (large) animal models and go straight into the patient population.
Location: Netherlands, Groningen
Employees: 11-50
Founded date: 2017
Mentions in press and media 1
| Date | Title | Description |
| 18.04.2023 | Annexin reports first imaging-study results in Retinal Vein Occlusion | Annexin reports first imaging-study results in Retinal Vein Occlusion Tue, Apr 18, 2023 08:30 CET Report this content Annexin Pharmaceuticals AB (“Annexin”) provides an update on its ongoing clinical study in patients with Retinal Vein Occl... |